{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:01:32Z","timestamp":1790114492296,"version":"4.0.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold> To assess the frequency of monitoring of adverse drug reaction (ADR) related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics and the considerations when monitoring was not performed.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This retrospective follow-up study included 100 randomly selected outpatients aged \u226418 years who had a first prescription of an antipsychotic drug recorded in the electronic medical records of psychiatric outpatient clinics between 2014 and 2017. They were followed for up to 3 years. This study assessed the frequency of monitoring for physical parameters (weight, height, body mass index, waist circumference, pulse, blood pressure, and an electrocardiogram) and laboratory parameters (glucose, lipids, and prolactin) before the first prescription of an antipsychotic drug as well as during its use. Monitoring frequencies were stratified by the patient characteristics (sex, age, cardiovascular risk factors, and use of other psychotropic drugs), and by location of antipsychotic drug initiation (psychiatric outpatient clinic or elsewhere). Additionally, this study assessed the considerations mentioned in the medical records for not monitoring ADR-related parameters.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Overall, physical parameters were monitored more frequently (weight: 85.9% during the first half-year) than laboratory parameters (glucose and cholesterol: both 23.5%). There were no significant differences in monitoring at least one physical as well as in monitoring at least one laboratory parameter during the baseline period and during the total follow-up of antipsychotic drug treatment between the patient characteristics. In total, 3% of the children and adolescents were never monitored for any physical parameter, and 54% were never monitored for any laboratory parameter. For a minority of the children (14.8%) who were never monitored for laboratory parameters, considerations were recorded in their medical records, including refusal by the child or parents and monitoring performed by the general practitioner or elsewhere.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Monitoring frequencies of ADR-related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics varied and especially monitoring of laboratory parameters was infrequent. Considerations why monitoring was not performed were rarely recorded. The optimal method of monitoring and documentation thereof should become clear to optimize the benefit-risk balance of antipsychotic drug treatment for each child.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.640377","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:17:53Z","timestamp":1614237473000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Monitoring of Adverse Drug Reaction-Related Parameters in Children and Adolescents Treated With Antipsychotic Drugs in Psychiatric Outpatient Clinics"],"prefix":"10.3389","volume":"12","author":[{"given":"Lenneke","family":"Minjon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivona","family":"Brozina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine C. G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eibert R.","family":"Heerdink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"van den Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/cap.2019.0018","article-title":"The pharmacoepidemiology of psychotropic medication use in Canadian children from 2012 to 2016","volume":"29","author":"Pringsheim","year":"2019","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1017\/S2045796020000293","article-title":"Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study","volume":"29","author":"Kaguelidou","year":"2020","journal-title":"Epidemiol Psychiatr Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","article-title":"National trends in off-label use of atypical antipsychotics in children and adolescents in the United States","volume":"95","author":"Sohn","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"B4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13052-016-0259-2","article-title":"Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists","volume":"42","author":"Pisano","year":"2016","journal-title":"Ital J Pediatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1089\/cap.2018.0139","article-title":"Reported adverse drug reactions in children and adolescents treated with antipsychotics","volume":"29","author":"Minjon","year":"2019","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jpeds.2018.12.033","article-title":"A comparison of pediatric and adult safety studies for antipsychotic and antidepressant drugs submitted to the United States Food and Drug Administration","volume":"208","author":"Liu","year":"2019","journal-title":"J Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord."},{"key":"B9","unstructured":"Formularium Psychofarmaca Accare; Monitoring op metabole en endocriene bijwerkingen van antipsychotica [Protocol; Monitoring for metabolic and endocrine adverse effects of antipsychotics]2014"},{"key":"B10","unstructured":"Psychosis and schizophrenia in children and young people: recognition and management; NICE Clinical Guideline 1552013"},{"key":"B11","first-page":"218","article-title":"The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"20","author":"Pringsheim","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/0269881115609016","article-title":"Instructions for clinical and biomarker monitoring in the Summary of product characteristics (SmPC) for psychotropic drugs: overview and applicability in clinical practice","volume":"29","author":"Nederlof","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1089\/cap.2018.0013","article-title":"Glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy","volume":"28","author":"Okumura","year":"2018","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/JCP.0000000000000936","article-title":"Monitoring of metabolic, cardiac, and endocrine indicators in youth treated with antipsychotics as reported by health care professionals","volume":"38","author":"Minjon","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamapediatrics.2014.224","article-title":"Metabolic monitoring in commercially insured pediatric patients newly initiated to take a second-generation antipsychotic","volume":"168","author":"Delate","year":"2014","journal-title":"JAMA Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/cap.2019.0087","article-title":"Metabolic monitoring rates of youth treated with second-generation antipsychotics in usual care: results of a large US national commercial health plan","volume":"30","author":"Hayden","year":"2020","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B17","unstructured":"Obesitas bij kinderen en adolescenten; leidraad voor kinderartsen [Obesity in children and adolescents; guidance for pediatricians]\n            van den AkkerELT\n            VreugdenhilA\n            HustinxSR\n            VerkaaikM\n            HoudijkM\n            van MilE\n          2018"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1097\/MJT.0000000000000853","article-title":"Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers","volume":"27","author":"Wakefield","year":"2020","journal-title":"Am J Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/cap.2014.0156","article-title":"Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics","volume":"25","author":"Rodday","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1308","DOI":"10.1542\/peds.2014-0828","article-title":"Adherence to guidelines for glucose assessment in starting second-generation antipsychotics","volume":"134","author":"Raebel","year":"2014","journal-title":"Pediatrics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","article-title":"Metabolic screening in children receiving antipsychotic drug treatment","volume":"164","author":"Morrato","year":"2010","journal-title":"Arch Pediatr Adolesc Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs."},{"key":"B23","unstructured":"Practice parameter for the use of atypical antipsychotic medications in children and adolescents2011"},{"key":"B24","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1089\/cap.2017.0034","article-title":"Improving cardiometabolic monitoring of children on antipsychotics","volume":"27","author":"Cotes","year":"2017","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0897190017752712","article-title":"Monitoring of metabolic adverse effects associated with atypical antipsychotics use in an outpatient psychiatric clinic","volume":"32","author":"Pereira","year":"2019","journal-title":"J Pharm Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bdi.12730","article-title":"Compliance with the guidelines for laboratory monitoring of patients treated with lithium: a retrospective follow-up study among ambulatory patients in the Netherlands","volume":"21","author":"Nederlof","year":"2019","journal-title":"Bipolar Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2333392819844635","article-title":"Adherence to monitoring guidelines of amiodarone adverse reactions","volume":"6","author":"Lavon","year":"2019","journal-title":"Heal Serv Res Manag Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e012818","DOI":"10.1136\/bmjopen-2016-012818","article-title":"Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study","volume":"7","author":"Schmidt","year":"2017","journal-title":"BMJ Open."},{"key":"B29","first-page":"134","article-title":"Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth","volume":"20","author":"Ronsley","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.schres.2012.08.031","article-title":"Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists","volume":"143","author":"Parameswaran","year":"2013","journal-title":"Schizophr Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1176\/appi.ps.002542012","article-title":"Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication","volume":"64","author":"Mangurian","year":"2013","journal-title":"Psychiatr Serv."},{"key":"B32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/amiajnl-2014-002726","article-title":"Electronic health records improve clinical note quality","volume":"22","author":"Burke","year":"2015","journal-title":"J Am Med Informatics Assoc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1472-6963-2-22","article-title":"Quality and correlates of medical record documentation in the ambulatory care setting","volume":"2","author":"Soto","year":"2002","journal-title":"BMC Health Serv Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jar.12461","article-title":"Exploring barriers and facilitators in the implementation and use of guideline recommendations on antipsychotic drug prescriptions for people with intellectual disability","volume":"31","author":"Ramerman","year":"2018","journal-title":"J Appl Res Intellect Disabil."},{"key":"B35","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1176\/appi.ps.201500553","article-title":"Monitoring of patients on second-generation antipsychotics: a national survey of child psychiatrists","volume":"68","author":"McLaren","year":"2017","journal-title":"Psychiatr Serv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12888-017-1522-9","article-title":"Guidance by physicians and pharmacists during antidepressant therapy: patients' needs and suggestions for improvement","volume":"17","author":"Nederlof","year":"2017","journal-title":"BMC Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics. A systematic review and meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects","volume":"19","author":"Roke","year":"2009","journal-title":"J Child Adolesc Psychopharmacol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.640377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:18:29Z","timestamp":1614237509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.640377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":38,"alternative-id":["10.3389\/fpsyt.2021.640377"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.640377","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"640377"}}